- Home
- MASS vs LYEL Comparison
MASS vs LYEL Comparison
Compare MASS & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MASS
- LYEL
- Stock Information
- Founded
- MASS 2012
- LYEL 2018
- Country
- MASS United States
- LYEL United States
- Employees
- MASS N/A
- LYEL N/A
- Industry
- MASS Medical/Dental Instruments
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- MASS Health Care
- LYEL Health Care
- Exchange
- MASS Nasdaq
- LYEL Nasdaq
- Market Cap
- MASS 235.8M
- LYEL 207.7M
- IPO Year
- MASS 2020
- LYEL 2021
- Fundamental
- Price
- MASS $6.47
- LYEL $10.57
- Analyst Decision
- MASS Strong Buy
- LYEL Sell
- Analyst Count
- MASS 3
- LYEL 2
- Target Price
- MASS $8.00
- LYEL $15.00
- AVG Volume (30 Days)
- MASS 288.2K
- LYEL 69.7K
- Earning Date
- MASS 08-05-2025
- LYEL 08-19-2025
- Dividend Yield
- MASS N/A
- LYEL N/A
- EPS Growth
- MASS N/A
- LYEL N/A
- EPS
- MASS N/A
- LYEL N/A
- Revenue
- MASS $65,560,000.00
- LYEL $65,000.00
- Revenue This Year
- MASS N/A
- LYEL N/A
- Revenue Next Year
- MASS $22.06
- LYEL N/A
- P/E Ratio
- MASS N/A
- LYEL N/A
- Revenue Growth
- MASS 37.93
- LYEL N/A
- 52 Week Low
- MASS $1.81
- LYEL $7.65
- 52 Week High
- MASS $8.06
- LYEL $32.40
- Technical
- Relative Strength Index (RSI)
- MASS 45.31
- LYEL 48.30
- Support Level
- MASS $6.17
- LYEL $10.01
- Resistance Level
- MASS $6.79
- LYEL $12.00
- Average True Range (ATR)
- MASS 0.40
- LYEL 1.01
- MACD
- MASS -0.06
- LYEL -0.17
- Stochastic Oscillator
- MASS 47.27
- LYEL 13.42
About MASS 908 Devices Inc.
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.